Hereditary Cancer Syndromes > BRIP1, BARD1, RAD51C, RAD51D

Cancer Risks

Cancer Risks

Cancer Risks

Cancer Risks

Associated Syndrome

Summary Cancer Risk Table for All Genes

 

CANCER TYPE GENETIC CANCER RISK 
Ovarian High Risk

gene Cancer Risk Tables

 

BARD1

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION
Ovarian To age 80 20% 10.2%

 

BRIP1

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION
Ovarian To age 80 5.8% 1.0%

 

RAD51C

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION
Ovarian To age 50 1.0% 0.2%
  To age 80 6.7% 1.0%

 

RAD51D

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION
Ovarian To age 50 2.3% 0.2%
  To age 80 14.8% 1.0%

Cancer Risk Management Tables

 

BARD1

CANCER TYPE PROCEDURE AGE TO BEGIN

FREQUENCY

Female Breast Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increased risk for breast cancer warrants consideration of individualized breast cancer risk-reduction strategies, such as the modification of standard population screening recommendations by starting screening at younger ages, performing screenings at greater frequency, and utilizing more sensitive technologies such as breast MRI. Individualized NA (Unless otherwise indicated by findings)

 

BRIP1 

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA

 

Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents. Individualized NA

 

RAD51C

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA
  Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk reduction strategies using other currently available options, such as surveillance and the use of risk reducing agents. Individualized NA

 

RAD51D

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA
  Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents. Individualized NA

Unique Challenge and Issues